Skip to main content
NCBI home page
Journal of Medical Genetics logoLink to Journal of Medical Genetics
. 2000 Aug;37(8):567–571. doi: 10.1136/jmg.37.8.567

Ten years of presymptomatic testing for Huntington's disease: the experience of the UK Huntington's Disease Prediction Consortium

P Harper 1, C Lim 1, C David 1, P Disease 1
PMCID: PMC1734651  PMID: 10922381

Abstract

Data on all presymptomatic genetic tests for Huntington's disease (HD) in the UK have been collected over the 10 year period since testing became available as a service. A total of 2937 completed tests have been performed up to the end of 1997, 2502 based on specific mutation testing, feasible since late 1993.
A total of 93.1% of these were at 50% prior risk, with a significant excess of females (58.3%); 41.4% of results were abnormal or high risk, including 29.4% in subjects aged 60 or over. The trend in test numbers has currently levelled out at around 500 per year.
Almost all presymptomatic tests are carried out in National Health Service genetics centres, with a defined genetic counselling protocol and with availability now in all regions of the UK. The introduction and establishment of HD presymptomatic testing shows that this form of predictive medicine for Mendelian disorders can be successfully incorporated into National Health Service structures. The comprehensive collection of simple data allows trends in demand and outcomes to be monitored and has also been the foundation for more detailed specific studies. A comparable approach to data collection in other genetic disorders will be important as presymptomatic testing becomes more generally feasible.


Keywords: Huntington's disease; presymptomatic testing

Full Text

The Full Text of this article is available as a PDF (94.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Almqvist E. W., Bloch M., Brinkman R., Craufurd D., Hayden M. R. A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease. Am J Hum Genet. 1999 May;64(5):1293–1304. doi: 10.1086/302374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bloch M., Adam S., Wiggins S., Huggins M., Hayden M. R. Predictive testing for Huntington disease in Canada: the experience of those receiving an increased risk. Am J Med Genet. 1992 Feb 15;42(4):499–507. doi: 10.1002/ajmg.1320420416. [DOI] [PubMed] [Google Scholar]
  3. Brandt J., Quaid K. A., Folstein S. E., Garber P., Maestri N. E., Abbott M. H., Slavney P. R., Franz M. L., Kasch L., Kazazian H. H., Jr Presymptomatic diagnosis of delayed-onset disease with linked DNA markers. The experience in Huntington's disease. JAMA. 1989 Jun 2;261(21):3108–3114. [PubMed] [Google Scholar]
  4. Codori A. M., Brandt J. Psychological costs and benefits of predictive testing for Huntington's disease. Am J Med Genet. 1994 Sep 15;54(3):174–184. doi: 10.1002/ajmg.1320540304. [DOI] [PubMed] [Google Scholar]
  5. Conneally P. M. Huntington disease: genetics and epidemiology. Am J Hum Genet. 1984 May;36(3):506–526. [PMC free article] [PubMed] [Google Scholar]
  6. Craufurd D., Dodge A., Kerzin-Storrar L., Harris R. Uptake of presymptomatic predictive testing for Huntington's disease. Lancet. 1989 Sep 9;2(8663):603–605. doi: 10.1016/s0140-6736(89)90722-8. [DOI] [PubMed] [Google Scholar]
  7. Craufurd D., Tyler A. Predictive testing for Huntington's disease: protocol of the UK Huntington's Prediction Consortium. J Med Genet. 1992 Dec;29(12):915–918. doi: 10.1136/jmg.29.12.915. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Doh-ura K., Tateishi J., Kitamoto T., Sasaki H., Sakaki Y. Creutzfeldt-Jakob disease patients with congophilic kuru plaques have the missense variant prion protein common to Gerstmann-Sträussler syndrome. Ann Neurol. 1990 Feb;27(2):121–126. doi: 10.1002/ana.410270205. [DOI] [PubMed] [Google Scholar]
  9. Evans D. G., Maher E. R., Macleod R., Davies D. R., Craufurd D. Uptake of genetic testing for cancer predisposition. J Med Genet. 1997 Sep;34(9):746–748. doi: 10.1136/jmg.34.9.746. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gusella J. F., Wexler N. S., Conneally P. M., Naylor S. L., Anderson M. A., Tanzi R. E., Watkins P. C., Ottina K., Wallace M. R., Sakaguchi A. Y. A polymorphic DNA marker genetically linked to Huntington's disease. Nature. 1983 Nov 17;306(5940):234–238. doi: 10.1038/306234a0. [DOI] [PubMed] [Google Scholar]
  11. Harper P. S., Newcombe R. G. Age at onset and life table risks in genetic counselling for Huntington's disease. J Med Genet. 1992 Apr;29(4):239–242. doi: 10.1136/jmg.29.4.239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Harper P. S. The epidemiology of Huntington's disease. Hum Genet. 1992 Jun;89(4):365–376. doi: 10.1007/BF00194305. [DOI] [PubMed] [Google Scholar]
  13. Huggins M., Bloch M., Wiggins S., Adam S., Suchowersky O., Trew M., Klimek M., Greenberg C. R., Eleff M., Thompson L. P. Predictive testing for Huntington disease in Canada: adverse effects and unexpected results in those receiving a decreased risk. Am J Med Genet. 1992 Feb 15;42(4):508–515. doi: 10.1002/ajmg.1320420417. [DOI] [PubMed] [Google Scholar]
  14. Kremer B., Goldberg P., Andrew S. E., Theilmann J., Telenius H., Zeisler J., Squitieri F., Lin B., Bassett A., Almqvist E. A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats. N Engl J Med. 1994 May 19;330(20):1401–1406. doi: 10.1056/NEJM199405193302001. [DOI] [PubMed] [Google Scholar]
  15. MacMillan J. C., Snell R. G., Tyler A., Houlihan G. D., Fenton I., Cheadle J. P., Lazarou L. P., Shaw D. J., Harper P. S. Molecular analysis and clinical correlations of the Huntington's disease mutation. Lancet. 1993 Oct 16;342(8877):954–958. doi: 10.1016/0140-6736(93)92002-b. [DOI] [PubMed] [Google Scholar]
  16. Morris M. J., Tyler A., Lazarou L., Meredith L., Harper P. S. Problems in genetic prediction for Huntington's disease. Lancet. 1989 Sep 9;2(8663):601–603. doi: 10.1016/s0140-6736(89)90721-6. [DOI] [PubMed] [Google Scholar]
  17. Rosen D. R., Siddique T., Patterson D., Figlewicz D. A., Sapp P., Hentati A., Donaldson D., Goto J., O'Regan J. P., Deng H. X. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993 Mar 4;362(6415):59–62. doi: 10.1038/362059a0. [DOI] [PubMed] [Google Scholar]
  18. Sherrington R., Rogaev E. I., Liang Y., Rogaeva E. A., Levesque G., Ikeda M., Chi H., Lin C., Li G., Holman K. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 1995 Jun 29;375(6534):754–760. doi: 10.1038/375754a0. [DOI] [PubMed] [Google Scholar]
  19. Simpson S. A., Besson J., Alexander D., Allan K., Johnston A. W. One hundred requests for predictive testing for Huntington's disease. Clin Genet. 1992 Jun;41(6):326–330. doi: 10.1111/j.1399-0004.1992.tb03407.x. [DOI] [PubMed] [Google Scholar]
  20. Tyler A., Ball D., Craufurd D. Presymptomatic testing for Huntington's disease in the United Kingdom. The United Kingdom Huntington's Disease Prediction Consortium. BMJ. 1992 Jun 20;304(6842):1593–1596. doi: 10.1136/bmj.304.6842.1593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Warner J. P., Barron L. H., Brock D. J. A new polymerase chain reaction (PCR) assay for the trinucleotide repeat that is unstable and expanded on Huntington's disease chromosomes. Mol Cell Probes. 1993 Jun;7(3):235–239. doi: 10.1006/mcpr.1993.1034. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Publishing Group

RESOURCES